**Supplementary Methods Table 2.**

**Supplementary Methods Table 2.** *In vivo* drug treatments of the combination therapy in BT183 xenografts are listed with their respective number of treated animals, dosing, administration, treatment schedule and dissolver of the compound. Vincristine and doxorubicin/topotecan are given in alternating weeks. For detailed treatment schedule see Figure 5A. *i.v. = intravenous; i.p. = intraperitoneal;*

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Treatment | # of animals | Dosis | Administration | Treatment schedule | Dissolver/Vehicle |
| DCC | Doxorubicin  (Caelyx®) |  | 7 mg/kg | i.p. | 2 consecutive days every second week | 5% Glucose/H2O |
| Methotrexate | 5 | 3 mg/kg | i.p. | 3 days per week | Saline |
| Vincristine |  | 0.5 mg/kg | i.v. | 2 days every second week | Saline |
| TCC | Topotecan | 5 | 2.5 mg/kg | i.p. | 3 days every second week | Saline |
| Methotrexate | 3 mg/kg | i.p. | 3 days per week | Saline |
| Vincristine | 0.5 mg/kg | i.v. | 2 days every second week | Saline |